Karyopharm Therapeutics Inc. (KPTI)
|52 Week Range||4.02-14.73|
|1y Target Est||-|
|DCF Unlevered||KPTI DCF ->|
|DCF Levered||KPTI LDCF ->|
|Debt / Equity||-453.92%||Strong Sell|
Upgrades & Downgrades
Latest KPTI news
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
15 June 2022
Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the...
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Me...
26 May 2022
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities ...
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
10 May 2022
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q1 2022 Results - Earnings Call Transcri...
5 May 2022
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng...
Karyopharm: Another 2 Year Wait For Data
5 May 2022
KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later.
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
28 April 2022
-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET -- NEWTON, Mass.
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
25 April 2022
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm to Participate at the Barclays Global Healthcare Conference
9 March 2022
NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...
Why Are Karyopharm Shares Trading Lower Today
2 March 2022
Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenan...